92.31
price up icon7.86%   6.73
after-market After Hours: 92.31
loading
Rhythm Pharmaceuticals Inc stock is traded at $92.31, with a volume of 1.90M. It is up +7.86% in the last 24 hours and up +6.98% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
See More
Previous Close:
$85.58
Open:
$93.9
24h Volume:
1.90M
Relative Volume:
2.25
Market Cap:
$6.33B
Revenue:
$189.76M
Net Income/Loss:
$-196.54M
P/E Ratio:
-29.69
EPS:
-3.1087
Net Cash Flow:
$-156.63M
1W Performance:
+9.66%
1M Performance:
+6.98%
6M Performance:
-7.20%
1Y Performance:
+43.32%
1-Day Range:
Value
$90.00
$99.00
1-Week Range:
Value
$79.40
$99.00
52-Week Range:
Value
$55.31
$122.20

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Name
Rhythm Pharmaceuticals Inc
Name
Phone
857-264-4280
Name
Address
222 BERKELEY STREET, BOSTON, MA
Name
Employee
414
Name
Twitter
@rhythmpharma
Name
Next Earnings Date
2026-05-05
Name
Latest SEC Filings
Name
RYTM's Discussions on Twitter

Compare RYTM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
RYTM icon
RYTM
Rhythm Pharmaceuticals Inc
92.31 5.86B 189.76M -196.54M -156.63M -3.1087
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 109.34B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 74.35B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 50.44B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 39.78B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.02B 5.36B 287.73M 924.18M 2.5229

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-19-26 Initiated RBC Capital Mkts Outperform
Nov-25-25 Initiated Citigroup Buy
Nov-05-25 Downgrade Oppenheimer Outperform → Perform
Jul-10-25 Initiated Goldman Buy
Jul-07-25 Initiated Leerink Partners Outperform
Apr-07-25 Upgrade BofA Securities Neutral → Buy
Mar-05-25 Resumed Stifel Buy
Jan-02-25 Initiated Jefferies Buy
Dec-20-24 Initiated Oppenheimer Outperform
Oct-21-24 Initiated Guggenheim Buy
Sep-18-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated JMP Securities Mkt Outperform
May-08-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-01-23 Upgrade BofA Securities Neutral → Buy
Jan-18-23 Resumed Canaccord Genuity Buy
Aug-08-22 Upgrade Goldman Neutral → Buy
Aug-05-22 Upgrade BofA Securities Underperform → Neutral
Jun-17-22 Reiterated Needham Buy
Mar-02-22 Resumed Stifel Buy
Feb-17-22 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-08-21 Initiated Wells Fargo Overweight
Nov-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-14-21 Resumed Goldman Neutral
Aug-04-21 Downgrade BofA Securities Neutral → Underperform
Aug-04-21 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-30-20 Downgrade BofA Securities Buy → Neutral
Jan-08-20 Initiated Goldman Sell
Jul-12-19 Upgrade Stifel Hold → Buy
Jul-08-19 Initiated Canaccord Genuity Buy
Mar-13-19 Initiated Ladenburg Thalmann Buy
Sep-07-18 Resumed Morgan Stanley Overweight
Jun-25-18 Reiterated Needham Buy
Jun-15-18 Reiterated Needham Buy
Oct-30-17 Initiated BofA/Merrill Buy
Oct-30-17 Initiated Needham Buy
View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

pulisher
08:00 AM

Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - Yahoo Finance

08:00 AM
pulisher
04:41 AM

Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo

04:41 AM
pulisher
04:20 AM

Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

04:20 AM
pulisher
04:15 AM

Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan

04:15 AM
pulisher
03:19 AM

Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance

03:19 AM
pulisher
12:11 PM

Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)? - Sahm

12:11 PM
pulisher
11:37 AM

Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com - Investing.com Canada

11:37 AM
pulisher
10:28 AM

Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN

10:28 AM
pulisher
10:14 AM

Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch - Investing.com

10:14 AM
pulisher
09:31 AM

Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

09:31 AM
pulisher
09:09 AM

Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Benzinga

09:09 AM
pulisher
09:08 AM

Earnings call transcript: Rhythm Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com

09:08 AM
pulisher
08:23 AM

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates - ChartMill

08:23 AM
pulisher
07:48 AM

Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals - Stock Titan

07:48 AM
pulisher
07:36 AM

Rhythm Pharmaceuticals Q1 revenue rises 84% - TradingView

07:36 AM
pulisher
07:09 AM

Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M - Moomoo

07:09 AM
pulisher
07:05 AM

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - The Manila Times

07:05 AM
pulisher
07:03 AM

After FDA approval, rare-obesity drug draws 150 start forms in 6 weeks - Stock Titan

07:03 AM
pulisher
May 04, 2026

How The Rhythm Pharmaceuticals (RYTM) Narrative Is Shifting On EMANATE Results And IMCIVREE Expansion - Yahoo Finance

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals Q1 2026 earnings preview - MSN

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals (RYTM) Shares New Insights on Pediatric O - GuruFocus

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals earnings in focus after obesity drug wins By Investing.com - Investing.com South Africa

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals earnings in focus after obesity drug wins - Investing.com UK

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society - The Manila Times

May 04, 2026
pulisher
May 04, 2026

Rare obesity trial: 44% of treated children reached healthy or overweight - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society - TradingView

May 04, 2026
pulisher
May 04, 2026

H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $105 - Moomoo

May 04, 2026
pulisher
May 03, 2026

MSN Money - MSN

May 03, 2026
pulisher
May 03, 2026

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

May 03, 2026
pulisher
May 01, 2026

Rhythm Pharmaceuticals Gains on European Approval for Obesity Drug By Investing.com - Investing.com Canada

May 01, 2026
pulisher
May 01, 2026

European Commission approves Imcivree for hypothalamic obesity - Investing.com

May 01, 2026
pulisher
May 01, 2026

European Commission approves Imcivree for hypothalamic obesity By Investing.com - Investing.com India

May 01, 2026
pulisher
May 01, 2026

Rhythm Pharmaceuticals, Inc. $RYTM Shares Bought by Jennison Associates LLC - MarketBeat

May 01, 2026
pulisher
May 01, 2026

Rhythm Pharmaceuticals Receives EC Authorization for First FDA-Approved Treatment of Acquired Hypothalamic Obesity in Europe - Quiver Quantitative

May 01, 2026
pulisher
May 01, 2026

Europe authorizes first drug for patients with relentless hunger - Stock Titan

May 01, 2026
pulisher
May 01, 2026

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - ChartMill

May 01, 2026
pulisher
May 01, 2026

MSN - MSN

May 01, 2026
pulisher
May 01, 2026

RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill

May 01, 2026
pulisher
Apr 30, 2026

Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Assessing Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Price Weakness - Sahm

Apr 30, 2026
pulisher
Apr 29, 2026

[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Pictet Asset Management Holding SA - MarketBeat

Apr 29, 2026
pulisher
Apr 28, 2026

Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN

Apr 28, 2026
pulisher
Apr 28, 2026

Rhythm Pharmaceuticals (RYTM) to Release Earnings on Tuesday - MarketBeat

Apr 28, 2026
pulisher
Apr 28, 2026

Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Apr 28, 2026
pulisher
Apr 27, 2026

Rhythm Pharma wins EU backing to expand Imcivree label - MSN

Apr 27, 2026
pulisher
Apr 27, 2026

Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines - Insider Monkey

Apr 27, 2026
pulisher
Apr 27, 2026

Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 60% Potential Upside In Biotech Sector - DirectorsTalk Interviews

Apr 27, 2026
pulisher
Apr 26, 2026

Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat

Apr 26, 2026

Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
Cap:     |  Volume (24h):